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INTRODUCTION
In surgical textbooks, enterocutaneous (EC) fistulas are 
described as surgical tragedies, catastrophes or disasters. 
Most EC fistulas occur following abdominal surgeries and 
only 15-25% of spontaneous EC fistulas are the result of 
underlying diseases such as Crohn’s disease, radiation 
enteritis or diverticular disease (1, 2). The incidence of 
traumatic EC fistula has been increasing due to the higher 
incidence of damage control surgery performed for major 
trauma (3).
EC fistulas are associated with significant morbidity and 
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mortality. Patients with EC fistula are faced with the burden 
of overcoming septic complications resulting from early 
intra-abdominal infection, fluid electrolyte imbalance and 
malnutrition. The goals of EC fistula management are to 
restore gastrointestinal (GI) continuity and allow enteral 
nutrition with minimal morbidity and mortality. A step-by-
step approach is recommended to achieve these goals. 
Management of EC Fistulas
Recognition and Stabilization of EC Fistula
The initial stage of EC fistula management consists of its 
identification, followed by general supportive care with fluid 
and electrolyte replacement, control of sepsis, nutritional 
support and control of fistula drainage by pharmacologic 
means as well as through skin protection. Once a post-
surgical or spontaneous EC fistula is identified, obtaining 
anatomic information is of the utmost importance to 
predict the site of intestinal opening and assess the need 
for surgery. Favorable external fistulas include esophageal, 
duodenal stump, pancreaticobiliary, and jejunal fistulas with 
small enteric defects (< 1 cm) and long tracts (> 2 cm). 
In contrast, gastric, lateral duodenal, ligament of Treitz, 
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and ileal fistulas are less likely to close spontaneously 
(4). Additionally, non-healing EC fistulas are associated 
with a Foreign body, Radiation, Inflammation, Infection, 
Inflammatory bowel disease, Epithelization of the fistula 
tract, Neoplasms and Distal obstructions (or FRIEND). 
The presence of any FRIEND component in EC fistula is an 
indication for surgical intervention; however, surgery should 
be performed only after sufficient time has been afforded 
to restore overall patient condition and allow lysis of the 
intra-abdominal fibrous adhesions from previous operations. 
Fistula output fluids rich in electrolytes, minerals and 
protein cause electrolyte imbalance and malnutrition. 
Fluid replacement therapy is therefore the first step in the 
management of patients with EC fistulas. Crystalloid, colloid 
solutions and blood transfusions are generally required 
during early resuscitation.
After initial resuscitation, septic complications need to 
be controlled. Treatment is comprised of intra-abdominal 
infection control with antibiotics, computed tomography 
(CT)-guided drainage or sometimes open drainage for a 
“controlled fistula”. A controlled fistula refers to an EC 
fistula without evidence of sepsis (high fever, rigors, and 
hypotension), or localized infection (cellulitis, pneumonia)
(5). If the intestinal contents drain out through the matured 
tract, there is no longer intraperitoneal contamination or 
fluid accumulation to cause septic problems. 
Sufficient parenteral or enteral nutritional support 
should be provided when the septic problems are under 
control. Parenteral nutrition has been shown to affect the 
spontaneous closure of EC fistulas (5-8). Recently, enteral 
feeding was found to have a protective effect on the 
mucosal barrier and immunologic function of the bowel, 
even in patients with high-output EC fistulas (9). Enteral 
feeding also improves hepatic protein synthesis. These 
advantages suggest that early enteral feeding with the 
combination of parenteral nutrition is a key component of 
nutritional support in patients with EC fistulas. A regular 
supplementation of trace minerals such as copper, zinc, and 
a vitamin complex is generally recommended. 
A fistula output greater than 500 mL per day is classified 
as a high-output fistula and less than 200 mL is classified 
as a low-output fistula. Fistula output is a significant 
single prognostic factor for determining the possibility of 
spontaneous closure and mortality (9-11). Control of output 
is therefore also very important in achieving spontaneous 
closure. Traditionally, NPO and nasogastric suction have 
been used to decrease output, but there is little evidence to 
support the effectiveness of these strategies. H2-receptor 
antagonists and proton pump inhibitors are recommended 
to control fistula output. Somatostatin and its analog, 
octreotide, inhibit endocrine and exocrine secretion in 
the GI tract. Recent randomized trials did not consistently 
show a positive effect of octreotide on fistula closure 
or a reduction in fistula output (12-15). High doses of 
antimotility drugs such as loperamide (up to 36 mg daily) 
and codeine phosphate (up to 240 mg daily) are also used 
to decrease fistula output (16).
Because the small bowel contents that drain from an EC 
fistula are rich in digestive enzymes and electrolytes, skin 
protection is a crucial step in wound management. It also 
aids in the secure closure of the abdomen when surgery is 
mandatory to control the fistula. Skin should be protected 
from maceration and breakdown when stoma appliances and 
protective films are used. Several studies of vacuum-assisted 
closure (VAC) reported successful closure of EC fistulas (2, 
5, 17), but the main advantages of VAC is skin protection 
and ease of dressing (Figs. 1, 2). Fibrin glue has also been 
introduced to close EC fistulas, but the success of the study 
was not definitive due to the small sample size (18).
Investigation to Defining the Anatomy of EC Fistula
After seven to ten days of general supportive care to 
stabilize patients and fistula output, an investigation to 
determine the anatomic location of the EC fistula should 
be considered. The gold-standard for examination of fistula 
anatomy involves a fistulogram using water-soluble contrast 
material (Fig. 3). The information gained via a fistulogram 
includes: 1) the source of the fistula; 2) the nature of the 
fistula such as length, course and relationship to the bowel; 
3) the absence or presence of bowel continuity (end vs. side 
fistula); 4) the absence or presence of distal obstruction; 5) 
the nature of the bowel adjacent to the fistula (inflammation 
and stricture); and 6) the absence or presence of an abscess 
cavity in communication with the fistula (5). Other studies 
such as abdominal CT scans and MRI of the abdomen also 
provide useful information in selected cases (16). 
Decision Making for Surgery
The duration of conservative management should be 
based on the anatomic studies of the fistula tract. In 
the absence of the adverse prognostic factors (FRIEND) 
described previously, the reported success rate of fistula 
closure varies from 30% to 74% in patients within a time 
frame of 4 to 12 weeks.
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Determining the optimal time for surgical intervention 
has not been well defined in the literature. However, 
surgery should be delayed until the intra-abdominal and 
systemic conditions of the patient are conducive to major 
surgery. Intraperitoneal adhesion can be performed from as 
early as postoperative day 4 and adhesive procedures are 
most frequently performed at postoperative day 35. Evenson 
and Fischer (5) proposed waiting at least four months 
from the date of the previous operation. Datta et al. (16) 
delayed the operation for a median of nine months from 
the initial surgery or the occurrence of a fistula. The timing 
of definitive surgery should be individualized according to 
patient characteristics. 
Surgery for EC Fistula
The aims of surgery for EC fistulas are: 1) 
refunctionalization of the entire bowel; 2) resection of the 
fistula with end-to-end anastomosis of the bowel; and 3) 
secure abdominal wall closure. Once surgery is planned, 
care should be taken not to injure the adjacent bowels 
while opening the abdomen. The fistula tract is detected 
by staining with methylene blue or guided probes. After 
identifying the fistula opening in the bowel, resection of the 
diseased bowel and end-to-end anastomosis is the preferred 
method compared to over-sewing the fistula opening of the 
bowel, as recurrent fistula is more likely after over-sewing 
(36%) than resection (16%) (19). To facilitate early feeding 
and decompression of the proximal bowel, selected cases 
require gastrostomy, diverting ileostomy or jejunostomy. 
Abdominal closure is challenging when fistula closure is 
attempted. Skin defects and the increased probability of 
wound contamination make secure skin closure difficult. 
Wound complications can result in new or recurring EC 
fistulas. To promote normal healing of the abdominal wound 
after surgery, optimal parenteral or enteral nutrition with 
a supplement comprised of trace minerals and vitamins is 
essential. 
Fig. 1. Application of vacuum-assisted closure systems in 
enterocutaneous fistulas. 
Fig. 2. Application of skin protection appliance after 
stabilization of enterocutaneous fistula. 
Fig. 3. Fistulogram with water soluble contrast material 
provided detailed information regarding anatomy of 
enterocutaneous fistula. 
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CONCLUSION
Treatment of EC fistula remains a surgical challenge 
despite the recent improvement of supportive patient care. 
Once EC fistula occurs, adequate stabilization of the patient, 
a thorough investigation of the fistula anatomy, and non-
operative management should intially be attempted. If 
surgery is required, careful planning, meticulous dissection, 
resection of the bowel, reanastomosis and reconstruction 
of the abdominal wall are critical. A multi-disciplinary 
team approach with a gastroenterologist, interventional 
radiologists, dieticians, enterostomal therapy nurses and 
surgeons will maximize successful EC fistula closure. 
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